India Launches Indigenous H5N1 Bird Flu Vaccine and Announces ₹300 Crore Laboratory

Union Minister for Agriculture and Farmers' Welfare and Rural Development Shri Shivraj Singh Chouhan dedicated India's first indigenous chicken vaccine against Avian Influenza (H5N1), commonly known as bird flu, to the nation at a program in Bhopal. The vaccine is priced at an affordable ₹1-2 per dose, making it accessible to small poultry farmers, and is described as the world's first vaccine against this particular variant of bird flu. The Minister simultaneously announced the establishment of a new state-of-the-art laboratory in Bhopal at an estimated cost of ₹300 crore to enhance animal disease research capabilities.

Economic Significance and Disease Impact

Shri Chouhan highlighted the substantial economic burden of animal diseases on India's economy, revealing that animal husbandry contributes 14% to India's GDP while the poultry sector accounts for another 1%. Specific disease-related economic losses were quantified: Foot and Mouth Disease causes average annual losses of ₹22,000 crore, Lumpy Skin Disease results in losses of ₹20,000 crore, Brucellosis accounts for ₹9,212 crore, and Peste des Petits Ruminants causes losses of ₹4,683 crore, totaling approximately ₹56,000 crore in annual losses to the country and its farmers.

Historical Context and Outbreak Data

India's first bird flu outbreak was reported in 2006 in Navapur, Maharashtra, resulting in the death of 10 lakh chickens with additional lakhs culled to contain infection. Subsequent outbreaks included 9 lakh chicken deaths in 2021 and 2 lakh deaths this year. Since 2006, India has witnessed more than 500 bird flu outbreaks, causing significant damage to the poultry industry while also posing transmission risks to mammals and humans.

Vaccination Achievements and Scientific Development

The National Animal Disease Control Program has administered 147 crore 16 lakh free vaccine doses against Foot and Mouth Disease so far, with Brucellosis reportedly brought under control. During the 2022 Lumpy Skin Disease outbreak, 32 lakh 80 thousand animals were infected and 1 lakh 86 thousand animals died, leading to the development of the 'Lumpi-ProVacInd' vaccine. ICAR-NIHSAD in Bhopal has previously developed indigenous vaccines for Gumboro disease, Brucella abortus S-19 Delta, Classical Swine Fever, and African Swine Fever.

Scientific Team and Research Process

The H5N1 vaccine was developed by a research team comprising Dr. S. Nagarajan, Dr. Manoj Kumar, Dr. C. Tosh, Dr. H. V. Murugkar, Dr. Aniket Sanyal, Dr. Senthil Kumar D., Dr. Naveen Kumar, and Dr. Yogisharadhya R. The scientists worked continuously for months, foregoing Saturday and Sunday holidays, while adhering to stringent biosafety protocols that required sanitization procedures, using 120 litres of water daily for bathing, and refraining from keeping pets at home throughout the research period.